Limits...
A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours.

Krona C, Ejeskär K, Carén H, Abel F, Sjöberg RM, Martinsson T - Br. J. Cancer (2004)

Bottom Line: A reduced pattern of expression was also observed in a set of various tumour types.Furthermore, we determined the genomic organisation of APITD1.We suggest that low expression of this gene might interfere with the ability for apoptosis through the p53 pathway.

View Article: PubMed Central - PubMed

Affiliation: 1Department of Clinical Genetics, Institute for the Health of Women and Children, Göteborg University, Sahlgrenska University Hospital-East, SE-41685 Gothenburg, Sweden.

ABSTRACT
Neuroblastoma is characterised by a lack of TP53 mutations and no other tumour suppressor gene consistently inactivated has yet been identified in this childhood cancer form. Characterisation of a new gene, denoted APITD1, in the neuroblastoma tumour suppressor candidate region in chromosome 1p36.22 reveals that APITD1 contains a predicted TFIID-31 domain, representing the TATA box-binding protein-associated factor, TAF(II)31, which is required for p53-mediated transcription activation. Two different transcripts of this gene were shown to be ubiquitously expressed, one of them with an elevated expression in foetal tissues. Primary neuroblastoma tumours of all different stages showed either very weak or no measurable APITD1 expression, contrary to the level of expression observed in neuroblastoma cell lines. A reduced pattern of expression was also observed in a set of various tumour types. APITD1 was functionally tested by adding APITD1 mRNA to neuroblastoma cells, leading to the cell growth to be reduced up to 90% compared to control cells, suggesting APITD1 to have a role in a cell death pathway. Furthermore, we determined the genomic organisation of APITD1. Automated genomic DNA sequencing of the coding region of the gene as well as the promoter sequence in 44 neuroblastoma tumours did not reveal any loss-of-function mutations, indicating that mutations in APITD1 is not a common abnormality of neuroblastoma tumours. We suggest that low expression of this gene might interfere with the ability for apoptosis through the p53 pathway.

Show MeSH

Related in: MedlinePlus

Comparative growth curves of cell lines after transfection of 1.5 μg GFP mRNA; 0.3 μg APITD1A mRNA+1.2 μg GFP mRNA or 1.5 μg APITD1A mRNA, respectively. (A) SK-N-AS (neuroblastoma). (B) SK-N-BE(2) (neuroblastoma). (C) K562 (lymphoblast). (D) 293 (transformed embryonal kidney).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747717&req=5

fig7: Comparative growth curves of cell lines after transfection of 1.5 μg GFP mRNA; 0.3 μg APITD1A mRNA+1.2 μg GFP mRNA or 1.5 μg APITD1A mRNA, respectively. (A) SK-N-AS (neuroblastoma). (B) SK-N-BE(2) (neuroblastoma). (C) K562 (lymphoblast). (D) 293 (transformed embryonal kidney).

Mentions: The mRNA transfection experiments showed that by adding 1.5 μg of APITD1A mRNA to the neuroblastoma cell line SK-N-AS the cell number was reduced by 70% after 24 h, and by 90% after 2–4 days of incubation, compared to GFP mRNA-transfected cells. If 0.3 μg APITD1A mRNA was mixed with 1.2 μg of GFP mRNA, the reductions in cell numbers after 24 h were 40% and 65% after 2–4 days (Figure 7AFigure 7


A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours.

Krona C, Ejeskär K, Carén H, Abel F, Sjöberg RM, Martinsson T - Br. J. Cancer (2004)

Comparative growth curves of cell lines after transfection of 1.5 μg GFP mRNA; 0.3 μg APITD1A mRNA+1.2 μg GFP mRNA or 1.5 μg APITD1A mRNA, respectively. (A) SK-N-AS (neuroblastoma). (B) SK-N-BE(2) (neuroblastoma). (C) K562 (lymphoblast). (D) 293 (transformed embryonal kidney).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747717&req=5

fig7: Comparative growth curves of cell lines after transfection of 1.5 μg GFP mRNA; 0.3 μg APITD1A mRNA+1.2 μg GFP mRNA or 1.5 μg APITD1A mRNA, respectively. (A) SK-N-AS (neuroblastoma). (B) SK-N-BE(2) (neuroblastoma). (C) K562 (lymphoblast). (D) 293 (transformed embryonal kidney).
Mentions: The mRNA transfection experiments showed that by adding 1.5 μg of APITD1A mRNA to the neuroblastoma cell line SK-N-AS the cell number was reduced by 70% after 24 h, and by 90% after 2–4 days of incubation, compared to GFP mRNA-transfected cells. If 0.3 μg APITD1A mRNA was mixed with 1.2 μg of GFP mRNA, the reductions in cell numbers after 24 h were 40% and 65% after 2–4 days (Figure 7AFigure 7

Bottom Line: A reduced pattern of expression was also observed in a set of various tumour types.Furthermore, we determined the genomic organisation of APITD1.We suggest that low expression of this gene might interfere with the ability for apoptosis through the p53 pathway.

View Article: PubMed Central - PubMed

Affiliation: 1Department of Clinical Genetics, Institute for the Health of Women and Children, Göteborg University, Sahlgrenska University Hospital-East, SE-41685 Gothenburg, Sweden.

ABSTRACT
Neuroblastoma is characterised by a lack of TP53 mutations and no other tumour suppressor gene consistently inactivated has yet been identified in this childhood cancer form. Characterisation of a new gene, denoted APITD1, in the neuroblastoma tumour suppressor candidate region in chromosome 1p36.22 reveals that APITD1 contains a predicted TFIID-31 domain, representing the TATA box-binding protein-associated factor, TAF(II)31, which is required for p53-mediated transcription activation. Two different transcripts of this gene were shown to be ubiquitously expressed, one of them with an elevated expression in foetal tissues. Primary neuroblastoma tumours of all different stages showed either very weak or no measurable APITD1 expression, contrary to the level of expression observed in neuroblastoma cell lines. A reduced pattern of expression was also observed in a set of various tumour types. APITD1 was functionally tested by adding APITD1 mRNA to neuroblastoma cells, leading to the cell growth to be reduced up to 90% compared to control cells, suggesting APITD1 to have a role in a cell death pathway. Furthermore, we determined the genomic organisation of APITD1. Automated genomic DNA sequencing of the coding region of the gene as well as the promoter sequence in 44 neuroblastoma tumours did not reveal any loss-of-function mutations, indicating that mutations in APITD1 is not a common abnormality of neuroblastoma tumours. We suggest that low expression of this gene might interfere with the ability for apoptosis through the p53 pathway.

Show MeSH
Related in: MedlinePlus